## **Core Concept**
Magnesium sulfate is a cornerstone in the prevention and treatment of eclampsia in preeclampsia. It acts as an NMDA receptor antagonist and has a role in blocking calcium channels, which helps in reducing neuronal excitability. However, its administration, especially in patients with renal impairment, requires careful consideration due to the risk of magnesium toxicity.

## **Why the Correct Answer is Right**
In patients with elevated serum creatinine, indicating impaired renal function, the clearance of magnesium is reduced. Magnesium sulfate is primarily excreted by the kidneys. If renal function is compromised, magnesium can accumulate to toxic levels, leading to muscle weakness, respiratory failure, and cardiac arrest. The **Zielinski regimen** or a **low-dose regimen** might be considered in such cases to avoid toxicity. However, the most appropriate strategy involves reducing the dose or using a regimen that does not rely heavily on renal excretion for its clearance, or closely monitoring magnesium levels.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option might represent a standard dosing regimen not adjusted for renal impairment, which could lead to magnesium toxicity in a patient with elevated serum creatinine.
- **Option B:** Similarly, this could be another standard regimen not suitable for patients with renal impairment.
- **Option D:** This might represent an even higher dose or more rapid administration, which would be particularly risky in the setting of renal impairment.

## **Clinical Pearl / High-Yield Fact**
A critical clinical pearl is that in patients with renal impairment, magnesium sulfate should be administered cautiously, often with a reduced dose or an adjusted dosing interval to prevent toxicity. Monitoring of serum magnesium levels and clinical signs of toxicity (such as decreased urine output, muscle weakness, and respiratory distress) is crucial.

## **Correct Answer:** B.